Search

Mesenchymal stromal cells (MSCs) possess several characteristics that make them attractive as a potential adjunct therapy for acute and chronic infectious diseases. MSCs are well known for their impressive immunomodulatory, prorepair effects and clinical safety profile, however, the efficacy of MSCs in controlling bacterial infections, at least directly, remains unclear. Mycobacterium avium complex pulmonary disease (MAC-PD) is a chronic condition driven by multi-drug resistant bacteria for which there are no robust efficacious treatment strategies.